Prelude Therapeutics

是其中之一......

• Russell 3000;
• TOB Iconic 10,000.

Prelude Therapeutics 是一家在股票代码 PRLD (US) 下上市的公司。

查看带有其 20 名主要高管的组织结构图

Prelude Therapeutics 搜索最多的简介

• Kris Vaddi, Chief Executive Officer and Director
• Paul Friedman, Chairman of the Board
• David Bonita, Director

创建提醒
跟踪 Prelude Therapeutics 的高管变动

Prelude Therapeutics 拥有 2,327 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。

Popular M&A news in 生物技术

• Alentis Therapeutics 刚刚宣布为 181 筹款数百万美元。 (公布2024十一月20号).
• Metsera 刚刚宣布为 500 筹款数百万美元。 (公布2024十一月20号).
• TRexBio 刚刚宣布为 84 筹款数百万美元。 (公布2024十一月14号).

生物技术 行业的其他推荐联系人

• Scholar Rock 企业 Kristina Burow - Director
• UroGen 企业 Fred Cohen - Director
• Adaptimmune Therapeutics 企业 Ali Behbahani - Non-Executive Director

了解更多有关生物技术行业的信息 >

Prelude Therapeutics 的最新新闻稿

• News Releases - Prelude Therapeutics
• News Releases - Prelude Therapeutics
• News Releases - Prelude Therapeutics
• News Releases - Prelude Therapeutics
• Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial Results - Prelude Therapeutics
• Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology - Prelude Therapeutics
• Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference - Prelude Therapeutics
• Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in May - Prelude Therapeutics
• Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Prelude Therapeutics
• Prelude Therapeutics Announces First Quarter 2022 Financial Results and Operations Update - Prelude Therapeutics
• View more press releases Close

关于 Prelude Therapeutics 的社交媒体

• Prelude Therapeutics 在 维基百科、谷歌新闻 和 雅虎财经
• Prelude Therapeutics 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 David Bonita

查看组织结构图

Register to receive your alert

报告错误